Changes in the periodontal microbiota in patients undergoing comprehensive treatment for chronic generalized periodontitis with an IL-1ra receptor antagonist
DOI:
https://doi.org/10.14739/2310-1237.2026.1.355703Keywords:
dental care, generalized periodontitis, chronic periodontitis, inflammation, molecular markers, biochemical markers, maxillofacial region, inflammatory disease, comprehensive treatment, analysisAbstract
Chronic generalized periodontitis is one of the most prevalent inflammatory diseases of periodontal tissues, characterized by progressive destruction of the tooth-supporting apparatus and a high rate of recurrence. A key role in its pathogenesis is played by dysbiosis of the periodontal microbiome combined with a dysregulated immune response, particularly the overproduction of pro-inflammatory cytokines, among which interleukin-1 (IL-1) is of central importance.
The aim of the study was to evaluate the effect of an IL-1 receptor antagonist (IL-1ra) Anakinra on microbial contamination of periodontal pockets in patients with chronic generalized periodontitis during combined treatment..
Materials and methods. The study included 87 patients aged 25–65 years, who were divided into three groups: basic therapy (n = 34), basic therapy with Anakinra (n = 31), and basic therapy with Cholisal gel (n = 22). Microbiological assessment was performed using quantitative PCR with identification of key periodontal pathogens.
Results. It was found that before treatment all patients exhibited a high level of microbial contamination (5.8–6.3 log10 CFU/mL), with predominance of red complex bacteria. The use of Anakinra resulted in a significantly greater reduction in bacterial load as early as 30 days (by 38.6–42.5 %, p < 0.001) compared to basic therapy and the comparison group. After 90 days, microbial reduction in this group reached 55.5–72.5 %, with levels decreasing to 2.6–3.1 log10 CFU/mL. The most pronounced reduction was observed for Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola, confirming the role of IL-1 in shaping a pathogenic microbial environment. The effect of Anakinra was shown to be indirect and mediated through modification of the inflammatory microenvironment, thereby limiting the persistence of anaerobic bacteria.
Conclusions. The obtained results demonstrated the high efficacy of IL-1ra (Anakinra) receptor antagonist in the complex treatment of periodontitis and substantiated its use as a pathogenetically targeted approach affecting both immune and microbiological mechanisms of disease progression.
References
- Martínez-García M, Hernández-Lemus E. Pro-Inflammatory and Anti-Inflammatory Interleukins in Periodontitis: Molecular Roles, Immune Crosstalk, and Therapeutic Perspectives. Int J Mol Sci. 2025;26(20):10094. doi: https://doi.org/10.3390/ijms262010094
| 
| 
- Neurath N, Kesting M. Cytokines in gingivitis and periodontitis: from pathogenesis to therapeutic targets. Front Immunol. 2024;15:1435054. doi: https://doi.org/10.3389/fimmu.2024.1435054
| | - Mehrnia N, Van Dyke TE. Microbial dysbiosis and immune dysregulation in periodontitis and peri-implantitis. Front Cell Infect Microbiol. 2026;15:1678163. doi: https://doi.org/10.3389/fcimb.2025.1678163
| | - Fernandes G, Mosley GA, Ross W, Dagher A, Martins B, Fernandes J. Revisiting Socransky's Complexes: A Review Suggesting Updated New Bacterial Clusters (GF-MoR Complexes) for Periodontal and Peri-Implant Diseases and Conditions. Microorganisms. 2024;12(11):2214. doi: https://doi.org/10.3390/microorganisms12112214
| | - Mazurek-Mochol M, Bonsmann T, Mochol M, Poniewierska-Baran A, Pawlik A. The Role of Interleukin 6 in Periodontitis and Its Complications. Int J Mol Sci. 2024;25(4):2146. doi: https://doi.org/10.3390/ijms25042146
| | - Gottschalk EC, Chabanovska O, Vasudevan P, Barrantes I, Kreikemeyer B, Bergmann-Ewert W, et al. Potential biomarkers for early periodontal inflammation: investigating CD5+ B cells, salivary cytokines and oral microbiome. Sci Rep. 2026;16(1):7192. doi: https://doi.org/10.1038/s41598-026-37044-6
| | - Cheng R, Wu Z, Li M, Shao M, Hu T. Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review. Int J Oral Sci. 2020;12(1):2. doi: https://doi.org/10.1038/s41368-019-0068-8
| | - Brodzikowska A, Górski B, Bogusławska-Kapała A. Effects of Interleukin-1 Genotype on the Clinical Efficacy of Non-Surgical Periodontal Treatment of Polish Patients with Periodontitis. Biomedicines. 2023;11(2):456. doi: https://doi.org/10.3390/biomedicines11020456
| | - Papathanasiou E, Conti P, Carinci F, Lauritano D, Theoharides TC. IL-1 Superfamily Members and Periodontal Diseases. J Dent Res. 2020;99(13):1425-34. doi: https://doi.org/10.1177/0022034520945209
| | - World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4. doi: https://doi.org/10.1001/jama.2013.281053
| | - Steemers E, Talbi WMI, Hogervorst JMA, Schoenmaker T, de Vries TJ. IL-1 Receptor Antagonist Anakinra Inhibits the Effect of IL-1β- Mediated Osteoclast Formation by Periodontal Ligament Fibroblasts. Biology (Basel). 2025;14(3):250. doi: https://doi.org/10.3390/biology14030250
| | - Plemmenos G, Evangeliou E, Polizogopoulos N, Chalazias A, Deligianni M, Piperi C. Central Regulatory Role of Cytokines in Periodontitis and Targeting Options. Curr Med Chem. 2021;28(15):3032-3058. doi: https://doi.org/10.2174/0929867327666200824112732
| | - Marchesan JT. Inflammasomes as contributors to periodontal disease. J Periodontol. 2020;91 Suppl 1(Suppl 1):S6-S11. doi: https://doi.org/10.1002/JPER.20-0157
| | - Li Y, He X, Luo G, Zhao J, Bai G, Xu D. Innovative strategies targeting oral microbial dysbiosis: unraveling mechanisms and advancing therapies for periodontitis. Front Cell Infect Microbiol. 2025;15:1556688. doi: https://doi.org/10.3389/fcimb.2025.1556688
| | - Martínez-García M, Hernández-Lemus E. Periodontal Inflammation and Systemic Diseases: An Overview. Front Physiol. 2021;12:709438. doi: https://doi.org/10.3389/fphys.2021.709438
| | - Higashi DL, Qin H, Borland C, Kreth J, Merritt J. An inflammatory paradox: strategies inflammophilic oral pathobionts employ to exploit innate immunity via neutrophil manipulation. Front Oral Health. 2024;5:1413842. doi: https://doi.org/10.3389/froh.2024.1413842
| | - Harrandah AM. The Oral-Gut-Systemic Axis: Emerging Insights into Periodontitis, Microbiota Dysbiosis, and Systemic Disease Interplay. Diagnostics (Basel). 2025;15(21):2784. doi: https://doi.org/10.3390/diagnostics15212784
| | - Messina BM, Polizzi A, Panuzzo C, Belmonte A, Angjelova A, Fuochi V, et al. Impact of Periodontal Host-Modulation Therapies on Oral-Gut Microbiome Axis in Periodontitis Patients with Hematological Diseases: A Narrative Review. Life (Basel). 2025;15(12):1862. doi: https://doi.org/10.3390/life15121862
| |
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 O. O. Dmytriieva, S. O. Chertov, S. D. Varzhapetian
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
